Global Blood Therapeutics, Inc.
GBT · NASDAQ
6/30/2022 | 3/31/2022 | 12/31/2021 | 9/30/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $2 | $2 |
| - Cash | $0 | $0 | $1 | $0 |
| + Debt | $1 | $1 | $1 | $0 |
| Enterprise Value | $2 | $3 | $2 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 29.7% | -1.7% | 7.8% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 98% | 98.1% | 97.9% | 98.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -100% | -128.3% | -143.5% | -125% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -115.3% | -147.6% | -163.1% | -136.4% |
| EPS Diluted | -1.26 | -1.26 | -1.42 | -1.13 |
| % Growth | 0% | 11.3% | -25.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |